Skip to main content
Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
FRESH Analysis Report
Aug 22, 2026
1 day ago · 100% complete
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for IQVIA Holdings Inc. (IQV) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Our current read (analysis of 2026-08-23): Designation Low · Gem Score -21 (−100…+100 Quality+Value blend) · Quality 37 · Value -68 · Sentiment 43 (timing only, not weighted) · Composite fair value $154.39 vs $259.82 at analysis

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysisthe core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at delvantic.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

IQVIA Holdings Inc.

IQV NYSE
Healthcare · Diagnostics & Research
Durham, NC 27703, United States iqvia.com Updated Aug 22, 4:05pm
Price
$259.82
Market Cap
$42.8B
Employees
94,000
Beta
1.18
Avg Volume
1,327,161
CEO
Mr. Ari Bousbib

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company supports pharmaceutical, biotechnology, medical device, and healthcare organizations in developing, testing, and commercializing therapies using extensive real-world data, predictive analytics, and technology platforms. Its Technology and Analytics Solutions segment delivers healthcare data, decision-support tools, and software to clients such as manufacturers, providers, payers, and policymakers, helping them optimize clinical and commercial performance. The Research and Development Solutions segment focuses on outsourced clinical trial services, including late-stage and virtual clinical trials for drugs, devices, and diagnostics. IQVIA also offers contract sales and medical solutions that assist with commercialization and field-based engagement. Founded in 1950 and headquartered in Durham, North Carolina, IQVIA plays a central role in the healthcare ecosystem by enabling more efficient evidence generation, regulatory submissions, and market access strategies across more than 100 countries worldwide.

Runs with full report Generated: Aug 22, 2026 4:12pm
Price Overview
Price at report time
$259.82
as of Aug 22, 4:05pm (1d ago)
Change · Aug 22
+3.77 (+1.47%)
Day Range
$254.93 – $260.40
52-Week Range
$154.50 – $260.40
50-Day MA
$212.96
200-Day MA
$199.52
Volume
1,307,300.00
Right now · live
Log in to get the live feed
Members see the real-time price and the move since this report (over 1d).
Share Structure
Outstanding 164,600,000.00
Float 156,249,842.00
Free Float 94.9%
High free float — 94.9% of shares trade freely, ~5.1% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Last updated: Aug 22, 2026 4:24pm (1d ago)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Aug 22, 2026 4:24pm (1d ago)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
TD Twelve Data statement HEX SEC filing
Industry comparison last run: Aug 22, 2026 4:10pm
P/E Ratio (Price per dollar of earnings)
HEX
Stock Price / EPS (Diluted)
33.14
Stock Price: $259.82
EPS (Diluted): 7.84
P/B Ratio (Price vs net asset value)
HEX
Stock Price / Book Value Per Share
6.80
Stock Price: $259.82
Total Equity: $6.63B
Shares: 173,500,000
EV/EBITDA (Total value vs operating profit)
HEX
Enterprise Value / EBITDA
17.56
Market Cap: $42.77B
Total Debt: $15.72B
Cash: $1.98B
EBITDA: $3.33B
Enterprise Value (Takeover price (cap + debt - cash))
HEX
Market Cap + Total Debt - Cash
$58.4B
Market Cap: $42.77B
Total Debt: $15.72B
Cash: $1.98B
Gross Margin (Revenue left after direct costs)
HEX
Gross Profit / Revenue
33.3%
Gross Profit: $5.43B
Revenue: $16.31B
Operating Margin (Revenue left after all operations)
HEX
Operating Income / Revenue
13.4%
Operating Income: $2.18B
Revenue: $16.31B
Net Margin (Revenue left as actual profit)
HEX
Net Income / Revenue
8.3%
Net Income: $1.36B
Revenue: $16.31B
ROE (Profit from shareholder equity)
HEX
Net Income / Total Equity
20.5%
Net Income: $1.36B
Total Equity: $6.63B
ROIC (Profit from all invested capital)
HEX
NOPAT / Invested Capital
9.0%
Operating Income: $2.18B
Tax Rate: 15.8%
Equity: $6.63B
Total Debt: $15.72B
Cash: $1.98B
Current Ratio (Can it pay short-term bills)
HEX
Current Assets / Current Liabilities
0.75
Current Assets: $6.25B
Current Liabilities: $8.34B
Debt/Equity (Leverage — debt vs equity)
HEX
Total Debt / Total Equity
2.37
Short-Term Debt: $1.84B
Long-Term Debt: $13.88B
Total Debt: $15.72B
Total Equity: $6.63B
Rev/Share (Top-line per share)
HEX
Revenue / Shares Outstanding
$94.01
Revenue: $16.31B
Shares: 173,500,000
Book Value/Share (Net assets per share)
HEX
(Total Assets - Total Liabilities) / Shares
$38.21
Total Equity: $6.63B
Shares: 173,500,000
FCF/Share (Real cash generated per share)
HEX
(Operating Cash Flow + CapEx) / Shares
$11.82
Operating CF: $2.65B
CapEx: -$603.00M
Shares: 173,500,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TD
Last Annual Dividend / Stock Price
Last Dividend: $0.00
Stock Price: $259.82
Payout Ratio (Earnings paid out as dividends)
HEX
Dividends Paid / Net Income
Dividends Paid: N/A
Net Income: $1.36B
Dividends paid not available in cash flow statement
Industry Benchmarks
Last run: Aug 22, 2026 4:10pm
Compares IQV against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Income Statement (Annual)
Last updated: Aug 22, 2026 4:24pm (1d ago)
Metric 2021 2022 2023 2024 2025
Revenue $13.9B $14.4B $15.0B $15.4B $16.3B
Cost of Revenue $9.2B $9.4B $9.7B $10.0B $10.9B
Gross Profit $4.6B $5.0B $5.2B $5.4B $5.4B
Operating Expenses $3.2B $3.2B $3.3B $3.2B $3.2B
Operating Income $1.4B $1.8B $2.0B $2.2B $2.2B
Net Income $966.0M $1.1B $1.4B $1.4B $1.4B
EBITDA $2.7B $2.9B $3.1B $3.3B $3.3B
EPS $5.05 $5.82 $7.39 $7.57 $7.91
EPS (Diluted) $4.95 $5.72 $7.29 $7.49 $7.84
Balance Sheet (Annual)
Last updated: Aug 22, 2026 4:05pm (1d ago)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $1.4B $1.2B $1.4B $1.7B $2.0B
Total Current Assets $4.8B $5.0B $5.6B $5.8B $6.2B
Total Assets $24.7B $25.3B $26.7B $26.9B $29.9B
Current Liabilities $5.2B $5.6B $6.5B $7.0B $8.3B
Long-Term Debt $12.0B $12.6B $13.0B $12.8B $13.9B
Total Liabilities $18.6B $19.6B $20.6B $20.8B $23.3B
Total Equity $6.0B $5.8B $6.1B $6.1B $6.6B
Retained Earnings $2.2B $3.3B $4.7B $6.1B $7.4B
Cash Flow (Annual)
Last updated: Aug 22, 2026 4:24pm (1d ago)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $2.9B $2.3B $2.1B $2.7B $2.7B
Capital Expenditure -$640.0M -$674.0M -$649.0M -$602.0M -$603.0M
Free Cash Flow $2.3B $1.6B $1.5B $2.1B $2.1B
Acquisitions (net) -$1.5B -$1.3B -$876.0M -$735.0M -$1.7B
Net Debt Issued / (Repaid) -$140.0M $616.0M $1.1B -$172.0M $1.3B
Dividends Paid
Stock Buybacks -$406.0M -$1.2B -$992.0M -$1.4B -$1.2B
Net Change in Cash -$448.0M -$150.0M $160.0M $326.0M $278.0M
Growth Trends (YoY %)
Last updated: Aug 22, 2026 4:24pm (1d ago)
Metric 2022 2023 2024 2025
Revenue Growth +3.9% +4.0% +2.8% +5.9%
Gross Profit Growth +8.3% +4.2% +2.6% +1.0%
Operating Income Growth +29.1% +9.9% +11.4% -0.9%
Net Income Growth +12.9% +24.5% +1.1% -0.9%
EBITDA Growth +10.2% +5.9% +6.9% +0.3%
0Company Classification 1Industry Landscape 2Company Momentum 3Forward Projection 4aDCF Valuation 4bEarnings Power Value 4cAnchored PE 4dReverse DCF 4eRevenue-Based DCF 4fAnchored P/S 4gScenario Analysis 4hDividend Discount Model 4iBook Value Analysis 4jInsider Activity 4fCash Flow Quality 4gDebt Maturity Risk 4hMacro Environment 4iSector Intelligence 4jRevenue Confidence 4kSensitivity Analysis 4lSector Demand Cycle 5AI Investigation 5bThesis Evaluation 6Valuation Synthesis
computed not applicable 18 computed · 6 not applicable
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-22 16:37
-0.1 : 1 recovery upside vs repeat-quarter downside
Even the bull case prices 3% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 73%.
CaseGrowthMarginFair valuevs price ($259.82)
Bull — recovery +12% 24.6% $250.90 -3%
Base — stabilizes +8% 21.4% $193.07 -26%
Bear — keeps slipping +4% 18.2% $145.27 -44%
Stress — last quarter repeats +5% 7.7% $69.79 -73%
The next quarters keep the trajectory of the worst recent matched quarter (ending 2025-06-30) — growth stays at 5.3% and margins bend by the same profit-vs-revenue ratio (×0.92). Stress is a trajectory, not a prediction — it answers "what if the ship's current heading simply continues," which history says is the case to respect.
Why this is appearing: this company files quarterly, so its recent trajectory could be measured rather than assumed — the engine matched Mar 2026 against the same quarter one year earlier and found revenue +8.4% · operating income +3.6% · net income +10.0% year-over-year. That measured heading is what the stress case extends forward. Of those, the stress case extends the worst matched quarter — the one ending Jun 30, 2025 (revenue +5.3%, operating income -2.7% YoY) — not the average. Data measured through Mar 31, 2026 — this card recalculates automatically when the next quarterly filing is ingested. Companies without quarterly filings (many foreign listings) never show this card: with no measured trajectory, there is nothing honest to repeat.
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for IQV — it's generated by the pipeline (market-narrative step).
Growth Outlook
Analyzed 2026-08-22 16:35

The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.

Growing Mid-to-high single-digit revenue growth is re-accelerating off a soft 2024-25 base as R&DS bookings convert and TAS annuity data reprices, but operating income (+3.6% vs revenue +8.4%) shows the growth is coming with margin friction and well below the category's ~16% pace. conf 7/10
Share loss Category growing · Category (Diagnostics & Research) is expanding at ~16% revenue CAGR with margins widening industry-wide; IQVIA is growing 6-8% with roughly flat multi-year earnings and compressing operating leverage. It participates in the expansion but captures a shrinking slice of incremental spend.
Next 2 quarters
Growing
Backlog conversion plus the annuity data book makes 6-9% revenue growth the high-probability outcome; the recent quarter already printed +8.4% and the revenue series is 'steady' with 1.5% volatility. Nothing in the pipeline turns that in two prints.
≈ inline with expectations
Year 1
Growing
Full-year should land mid-to-high single digits on revenue with EPS growing faster than operating income via buyback. The constraint is margin: analytics mix and price concessions in services keep operating income growth below revenue growth for the year.
≈ inline with expectations
Years 2–3
Holding
Structurally this is a 4-6% compounder with roughly flat multi-year earnings CAGR (0.07%) — the moat protects the revenue base but does not generate expanding earnings power while services pricing is competed and the category grows three times faster. Share loss at -12.3pp is the structural fact that has to be assumed persistent absent evidence of reversal.
↓ below expectations
The creme: each rung's call measured against what's already printed (vs analyst estimates · vs guidance / FY consensus · vs price-implied growth) — expectations in print are already in the price, so only the variant margin can pay. Hover a rung's chip for the margin read.
Growth drivers
61 Contracted backlog conversion in R&DS — Clinical development revenue is booked years ahead; the latest matched-quarter print (+8.4% revenue) is roughly double the 4.3% multi-year CAGR, which is the signature of backlog burn accelerating rather than a one-off. That gives unusually high visibility on the next 2-4 prints.
50 TAS data/analytics annuity with contractual escalators — The real-world data and prescription-audit franchise is subscription-like with high renewal and embedded price escalators; it is the reason revenue volatility is only 1.5% and all years have been positive. This is the floor under the growth call, not the upside.
42 Pharma patent-cliff pipeline spend — The 2027-2030 loss-of-exclusivity wave forces large-cap pharma to push more assets through development and to buy more commercialization analytics; IQVIA is a default vendor at scale, which supports demand even if per-trial pricing is competitive.
28 EPS leverage from buyback and mix — Net income +10% against operating income +3.6%, plus four straight modest EPS beats (+4%, +3%, +14%), indicates below-the-line and share-count support. It makes the reported EPS line grow faster than the underlying business.
Growth risks
64 Underperformance versus a fast-growing category — Category median recent growth is ~16.3% and industry revenue CAGR 16.1% against IQVIA's 5.9-8.4%; a -12.3pp gap. Even allowing that a $16bn+ incumbent cannot match subsegment growth rates, the direction says peers (Medpace-type, diagnostics-levered names) are taking the incremental dollar.
54 Margin compression / commoditized service pricing — Operating income growing less than half as fast as revenue while industry margins expand +6.9pp is the clearest signal that clinical services pricing is being competed away and mix is shifting toward lower-value pass-through work.
40 Biotech funding sensitivity with 10y at 4.69% — Emerging-biopharma bookings — the historic growth engine — are rate-sensitive. A restrictive curve keeps small-cap trial starts and cancellation rates unfavourable, capping the acceleration case.
36 Large-pharma insourcing and R&D budget discipline — Post-IRA cost programs at major clients cut discretionary analytics spend first and pull selective trial work in-house; backlog cancellations are the transmission mechanism and they show up with a 2-3 quarter lag.
22 Leverage limits reinvestment optionality — A levered balance sheet means growth must be funded from cash flow (FCF CAGR 16.9% helps), but it constrains the ability to buy the fast-growing data/AI assets that would close the category gap.
Two forces dominate. First, pharma is spending more on late-stage development into the 2027-2030 patent cliff while simultaneously running hard cost discipline on commercial and analytics budgets — that mix favours IQVIA's contracted trial work and pressures its higher-margin advisory/analytics line, which is exactly the pattern in the +8.4% revenue / +3.6% operating income split. Second, capital cost matters more than sentiment here: a 4.69% 10-year keeps emerging-biopharma trial starts subdued, and that cohort is where incremental outsourcing growth historically came from. AI is genuinely two-sided for this company: it can compress the billable-hour content of monitoring and data management (revenue risk), but IQVIA's proprietary longitudinal patient and prescription data is the scarce input models need, which is the one asset a competitor cannot rebuild. Net: a durable, slow-compounding business inside a faster-moving category.
Growth position composite -8
ShrinkingStallingHoldingGrowingAccelerating
70Next 2 quarters · Growing
70Year 1 · Growing
50Years 2–3 · Holding
-8Composite (−100…+100)
A research prediction, not advice. Forward-graded: each rung is scored against the prints that follow it. Not an input to the GEM designation — track record first.
Claude Reading
Independent analyst synthesis · claude-opus-4-7 · generated 2026-08-22 16:24:06
Verdict Overvalued but not by 50% — fair value $190-210 range vs $260 current; wait for either a growth re-acceleration in H2 2026 or a pullback below $200 before committing.

The raw numbers tell a story of a business that has essentially stopped growing at the bottom line while carrying a leveraged balance sheet. Annual net income has been flat at ~$1.36B for three straight years (2023: $1.36B, 2024: $1.37B, 2025: $1.36B) despite revenue climbing from $14.98B to $16.31B — that's operating leverage running in reverse. Gross margin has been grinding lower (36.2% in 2022 → 33.3% in 2025), and the most recent quarter (Q1 2026) shows revenue of $4.15B with NI of just $274M (6.6% margin) — worse than Q1 2025's already-weak 6.5%. Debt of $15.72B against $6.63B equity (D/E 2.37) and cash of only $1.98B against a current ratio of 0.75 is not a "mature earner" balance sheet; it's a leveraged one that requires refinancing discipline in a still-elevated rate environment. FCF of $2.05B is real, but at a $42.8B market cap plus ~$13.7B net debt, EV/FCF is ~27x for a business growing revenue at ~5% and earnings at 0%.

The synthesis verdict ($124–154 fair value vs $260) is directionally right but I think the magnitude is aggressive. A DCF that spits out $154 on a business generating $2.05B of FCF implies you're assigning almost no terminal value credit to the data/TAS optionality — which is the whole reason IQV trades where it does. The Pre-Flight and Narrative layers correctly identify that the market is paying a platform-monopoly multiple for what the P&L actually shows: a services grinder with 13.4% operating margins and no earnings growth. But Market Forces calling this a "deteriorating incumbent losing massive market share" overstates it — revenue is still growing 5.9% YoY and FCF CAGR of 16.9% (though this is partially working-capital driven and not matched by earnings CAGR of 0.1% — a red flag the synthesis undersells). The contradiction between "Strong Cash Flow Quality" and 0.1% earnings CAGR deserves more scrutiny: either D&A/SBC is masking real economic earnings, or working capital tailwinds are non-repeatable. I lean toward the latter given flat NI.

The contrarian case worth stress-testing: IQV's real-world data assets (IMS legacy + Q² acquisition + decades of trial data) genuinely are hard to replicate, and if biotech funding recovers in 2026-27, the CRO backlog could re-accelerate. Pharma R&D spend has been resilient at $250B+ globally, and GLP-1/oncology trial demand is structurally growing. At a $154 fair value the stock would trade at ~19x earnings and ~11x EV/EBITDA — that's pricing in secular decline, not maturity. The insider activity is unambiguously negative but modest in size (mostly option-exercise-and-sell mechanics, ~114K net shares sold across the cluster) — I wouldn't weight it heavily. What I would weight: the flat three-year earnings profile combined with gross margin compression from 36% to 33% suggests pricing power is eroding, not building — which directly contradicts the platform-monopoly narrative.

I partially agree with the synthesis but dissent on magnitude. Fair value is closer to $190–210, not $124. Getting to $154 requires assuming margin compression continues and multiple compresses to peer CRO levels (~15x) — plausible bear case but not base case for a business with genuine data moat elements. Getting to $260 requires the market's implied 25% FCF CAGR — implausible given the flat earnings trajectory and 33% gross margin. At $260, IQV is priced for a re-acceleration that the numbers do not support: Q1 2026 revenue growth of 8.4% YoY is fine, but the margin regression is not. The insider file, macro headwinds tag, and lagging sector peers signal all point the same direction, and the thesis evaluation's -8 score with bear mass of 88 vs bull mass of 80 is roughly where I land. This is a "wait for $195 or a re-rating catalyst" situation, not a "load the boat short" one. Data is reasonably current (Q1 2026 print available), but the 2026-dated insider transactions and quarterly data suggest the file has been synthetically forward-dated or contains a labeling quirk — worth flagging but doesn't change the analytical read.

GPT Reading
Independent reading · gpt-5.4 · generated 2026-08-22 16:24:22
Verdict Overvalued at $260 — strong franchise and cash flow, but flat earnings, soft margins, and high leverage support something closer to $200 than a premium-growth multiple.

IQVIA looks like a good business priced like a better one. The raw numbers say “steady compounder,” not “platform step-change.” Revenue has climbed from $13.87B in 2021 to $16.31B in 2025, about 4% annualized, and the quarterly run-rate shows the same mid-single-digit pace: 2026 Q1 revenue of $4.15B was up 8.4% from $3.83B a year earlier, following 2025 growth that was decent but hardly explosive. The issue is that earnings have not followed. Net income was $1.36B in 2023, $1.37B in 2024, and $1.36B again in 2025. So after two years of revenue growth, net income is flat. That is the central fact the valuation has to overcome, and at 33x earnings, 17.6x EV/EBITDA, and 2.8x sales, I don’t think it does.

Margins reinforce that this is a scale services business with limited incremental drop-through, not a software-like model hiding inside healthcare outsourcing. Gross margin was 35.7% in 2024 and fell to 33.3% in 2025 despite revenue growth. Operating income actually slipped from $2.20B to $2.18B year over year. Quarterly net margins are also choppy: 6.5%, 6.6%, 8.1%, 11.8%, then back to 6.6% in the latest quarter. Some seasonality is normal, but if the bull case is that data assets and analytics should steadily enrich mix and expand profitability, the reported pattern doesn’t show it yet. IQVIA does generate real cash — $2.65B of operating cash flow and $2.05B of free cash flow in 2025 is strong, roughly a 12.6% FCF margin — but even that only gives an FCF yield of about 4.8% on a $42.8B market cap. For a business growing revenue mid-single digits and earnings not at all, that is not cheap.

The balance sheet is the other reason I lean bearish rather than merely cautious. Debt is $15.72B against $1.98B of cash, so net debt is roughly $13.7B. Against 2025 operating income of $2.18B and ROIC of 9.0%, leverage is meaningful, especially with a current ratio below 0.75. This is not distress territory because the business is cash generative, but it absolutely matters for equity valuation: a highly levered mature services company should not command a premium multiple unless margin expansion or growth acceleration is evident. Instead, equity is only $6.63B, so the capital structure is doing a lot of the work in boosting ROE to 20.5%; that number flatters the economics more than it proves exceptional underlying returns. I also would not overread the insider sales, since option exercise-related selling is common, but the tape certainly doesn’t offer a counter-signal that management thinks the shares are glaringly cheap.

The best argument against my view is that IQVIA is not just a CRO, and the market may be correctly valuing durability over growth. A business that can produce over $2B of annual free cash flow, hold net income around $1.3B through mixed pharma spending cycles, and grow revenue from $14.98B to $16.31B in two years without blowing up margins does deserve a premium to lower-quality outsourced services names. You can also argue that 2025’s weaker gross and operating margins are temporary mix effects rather than structural deterioration, and that the latest quarter’s 8.4% revenue growth hints at reacceleration. If free cash flow can keep compounding faster than earnings — as it has over the past few years — then a P/E screen may be too punitive, particularly for a company with recurring customer relationships and embedded data assets. That is the strongest bull case: resilience plus cash conversion plus strategic positioning.

I’d still weigh those positives below the price because the market seems to be paying today for margin and growth that remain prospective. To change my mind, I would want to see two things in the reported numbers, not just in the narrative: first, sustained operating leverage, meaning annual operating income grows meaningfully faster than revenue and operating margin moves back above 14% rather than hovering around 13%; second, free cash flow pushing toward $2.6B-$3.0B without leverage increasing, which would make the current enterprise value look more reasonable. If the next few quarters show revenue holding above 7-8% growth while net margin stabilizes closer to 9-10% instead of 6-7%, the stock can support a higher base than I’m giving it. Absent that, $260 looks like a full price for a business whose actual reported earnings power has been flat.

Grok Reading
Independent reading · grok-4.5 · generated 2026-08-22 16:24:58
Verdict Overvalued at $260 — ~33× flat earnings and ~21× FCF for a 4–6% grower with $15.7B debt; fairer zone nearer $150–180 on current trajectory

The numbers on IQVIA describe a mature cash compounder that the market insists on valuing like a growth platform. Revenue climbed from $13.87B in 2021 to $16.31B in 2025—a 4.3% CAGR—with the latest year at 5.9% growth to $16.31B. That is respectable scale, not acceleration. Net income has gone nowhere: $1.36B in 2023, $1.37B in 2024, $1.36B in 2025, and trailing quarterly NI swinging between $249M and $514M with no upward slope (earnings CAGR essentially 0.1%, recent YoY −1%). Operating margin sits at 13.4% and net margin at 8.3%, both capped; gross margin of 33.3% has barely moved despite years of “tech-enabled” narrative. What does work is cash conversion: $2.65B operating CF and $2.05B FCF on $603M capex, an FCF CAGR of 16.9% that is the only metric justifying any premium. At a $42.8B equity value and roughly $56.5B EV (net debt ≈ $13.7B), you are paying ~21× FCF and 17.6× EV/EBITDA for mid-single-digit top-line growth and flat earnings. A 33× P/E on a business whose earnings have not compounded in three years is the core mismatch.

The balance sheet sharpens the risk. Total debt of $15.72B against $6.63B equity (D/E 2.37) and a current ratio of 0.75 leave little cushion; ROIC of 9.0% and ROA of 4.5% show that the 20.5% ROE is leverage theater, not superior capital returns. Quarterly revenue is grinding higher—$3.83B → $4.02B → $4.10B → $4.36B → $4.15B—but the margin pattern remains seasonal and unexpanded (Q1s stuck near 6.5–6.6%, one strong Q4 at 11.8%). Insider activity in mid-2026 was a wave of sales and option-related dispositions, not accumulation. The prior models’ “overvalued” call and the −8 thesis score align with the raw data: the stock embeds an implied path to something like 25% FCF growth that the income statement simply does not support. The platform-monopoly narrative is doing the heavy lifting; the fundamentals are a mid-single-digit CRO/data services grinder with high leverage.

The strongest case against this read is the FCF engine and the durability of the data franchise. Free cash flow of $2.05B with strong conversion quality is real, and if the 16.9% FCF CAGR persists while revenue merely compounds at 5–6%, equity value can still accrete even without multiple expansion. Pharma R&D outsourcing remains structural, hybrid/decentralized trials are a multi-year mix shift, and IQVIA’s real-world data assets are genuinely hard to replicate at scale—arguments the bull camp (and the 33× multiple) lean on. A smart opponent would also note that EV/revenue of 3.6× and P/S of 2.8× are not outrageous for a sticky healthcare infrastructure name if margins ever inflect, and that FCF yield near 5% is not zero in a quality compounder. I weigh this less heavily because earnings have stagnated, ROIC is mediocre after leverage, debt service and refinancing risk are non-trivial at $15.7B of debt, and every year without operating leverage makes the “AI/data monopoly” story look more like marketing cover for a services ceiling already visible in the 13% operating margin.

What would flip the verdict is concrete evidence that the narrative is becoming the P&L: two consecutive quarters of revenue growth sustainably above 8–9% with operating margin pushing through 15%, a clear multi-year path to $3B+ FCF without further leverage, and net debt/EBITDA trending down materially rather than sideways. A credible capital-return step-up (debt paydown plus buybacks) funded by FCF, or segment disclosure showing the analytics/TAS mix actually expanding margins, would also force a re-rating higher. Absent that, the $260 print remains a story price on mature-earner economics.

Big-3 Panel — where each AI stands
Each AI above independently stated a direction (undervalued, fairly valued, or overvalued) and how strongly it believes it (conviction, 0–5). We combine those into a Bull-Bear Index on a 0–10 scale: 5 is neutral, 10 is maximum bullish (undervalued at full conviction), 0 is maximum bearish. We compute the score ourselves with the same arithmetic for every seat — the models never grade their own bullishness — so the three are directly comparable. Δ shows how far each seat sits from the panel average of 1.3; a large Δ marks the dissenting voice, usually the one worth reading.
Claude claude-opus-4-7 2.0
overvalued · conviction 3/5 · Δ +0.7 vs panel · self: 3.0
GPT gpt-5.4 1.0
overvalued · conviction 4/5 · Δ -0.3 vs panel · self: 3.0
Grok grok-4.5 1.0
overvalued · conviction 4/5 · Δ -0.3 vs panel · self: 3.0
Advanced Analysis Forensic deep-dive · separate lenses
Separate reads — Company Quality (is it a great business?), Valuation (is it mispriced?), and General Sentiment (how macro + narrative are pushing it), kept deliberately apart · 2026-08-22 16:37:05
Delvantic - Cairn AI
Quality name, wait for a materially lower price 8/10
Solid mature CRO compounder trading ~70% above composite fair value on a live AI-platform narrative — pass at $260, patient bid in the $170s.
The cruxWhether the platform/AI narrative converts into re-accelerating revenue and margin expansion, or 2025's margin fatigue plus leverage reasserts itself and the multiple compresses toward the $150-200 fair-value cluster.
Forensic checks Derived mechanically from IQV's filed financials — not from the AI lenses
Liquidity & RunwaySelf-Funding
DilutionShare Count Shrinking
Earnings QualityHigh Earnings Quality
The four lensesswitch a tab for its full read — score + evidence
Company Quality
+37
Solid
edge √Σ 111 · risk √Σ 72 · conf 7/10

IQVIA is a mature earner: revenue grew from $13.87B (2021) to $16.31B (2025), a ~4% CAGR, with operating margin expanding from 10% to a 14.3% peak in 2024 before easing to 13.4% in 2025. Gross margin has been stable in the 33-35% band, and FCF has run $1.5-2.3B annually, funding a genuine per-share value story: diluted shares fell from 195.0M to 173.5M (-2.9% CAGR) with buybacks running ~5x SBC and SBC only 1.5% of revenue. Earnings quality checks are clean: OCF/NI 2.13x, accruals -5% of assets, Beneish M -2.59.

Strengths 4
m62
Genuine per-share compounding
Diluted shares down from 195.0M to 173.5M (-2.9% CAGR); buyback/SBC ratio of 499% means capital return is real, not just offsetting comp.
m58
Clean earnings quality
OCF/NI of 2.13x, accruals -5% of assets, Beneish M -2.59 - mechanical forensic checks find no manipulation signals.
m55
Consistent FCF generation
FCF ranged $1.50B-$2.30B across five years on growing revenue; self-funding with $2.05B most recently.
m45
Multi-year operating leverage
Operating margin expanded from 10% (2021) to 14.3% (2024) as revenue grew 17% cumulatively, though it slipped to 13.4% in 2025.
Concerns 3
m60
Sizeable net debt load
Net cash -$13.58B vs $2.14B liquid; Altman Z 2.15 in grey zone. Leverage is manageable given FCF but removes any balance-sheet cushion.
m35
2025 margin and earnings stall
Operating margin fell from 14.3% to 13.4% and net income was flat at $1.36B despite revenue rising to $16.31B - operating leverage reversed this year.
m20
Insider selling with zero buying
8 sales totaling $29.2M in last 12 months, 0 open-market buys; largely tied to option exercises so not a strong negative, but no conviction signal either.
This looks like a textbook mature compounder in a decent state - not a fortress because the balance sheet carries real leverage and 2025 showed the first hint of margin fatigue, but the cash generation, earnings integrity, and disciplined share shrink are the real deal. I'd grade it Solid, closer to the middle of the 62-75 band. Nothing in the forensic data suggests accounting games or capital-structure games; the concerns are ordinary business concerns (leverage, cyclical CRO demand) rather than integrity concerns.
Verify before trusting this (5)
  • Composition and maturity ladder of the $13.58B net debt and refinancing risk
  • Cause of 2025 operating margin compression (mix, pricing, or one-time)
  • Backlog and book-to-bill trends in the R&D Solutions segment
  • Customer concentration among top biopharma clients
  • Whether SBC is being netted against buyback authorization or on top
Valuation / Mispricing
-68
Rich
edge √Σ 25 · risk √Σ 109 · conf 6/10
Price $259.82 vs composite deserved ~$154 (signal-adj $124) - roughly 40-52% above fair, no margin of safety. attractive below $175.00

Every valuation lane lands well below the tape: DCF $158.75, anchored P/E $202.02, and an EPV floor of just $98.03, blending to a composite fair value of $154.39 and a signal-adjusted $123.95. Even the most generous of those, the anchored P/E, still implies about 22% downside from $259.82. The earnings-quality read is clean (score 2), so there is no haircut to apply, and the Company-Quality lens is only 'Solid' with real net debt - not a fortress that deserves a premium multiple on top of already-full lanes. The gap is the whole story: you are paying for the bull's platform-monopoly narrative in full. To justify $260 you need durable mid-to-high-single-digit revenue growth, margin expansion despite 2025's early margin fatigue, and continued aggressive buybacks - a stack of things going right on a levered, mature CRO. The bear case (commoditized clinical services, 2.1x sales, leverage) is not priced in at all. This isn't obviously overvalued to the point of shorting - the anchored-PE lane and buyback compounding give some support - but there is no margin of safety here, and I would not underwrite a purchase at this price.

Cheap signals 2
m20
Clean earnings quality, no haircut needed
Earnings-quality score of 2 (High) means the reported cash and EPS are trustworthy - deserved value doesn't get chopped further, which is a modest offset to the richness.
m15
Disciplined buybacks compound per-share value
Solid share shrink at a mature FCF generator provides a per-share tailwind that pure DCF and EPV lanes may under-credit.
Rich / priced-in 4
m72
Price ~70% above composite fair value
Composite FV $154.39 and signal-adjusted $123.95 vs $259.82 tape imply -40% to -52% downside. Three independent methods agree the stock is expensive.
m55
Even the friendliest lane says overvalued
Anchored-PE, the most generous method at $202.02, still sits 22% below the current price - so even accepting a peer-multiple premium doesn't rescue the valuation.
m45
EPV floor implies severe downside if growth stalls
EPV of $98.03 says the no-growth earnings power is worth ~38% of today's price - the market is capitalizing a lot of future growth into the current tape.
m40
Priced for platform-monopoly narrative
At 2.1x sales with meaningful net debt, the multiple assumes pricing power and AI-driven data monetization that a mature, competitive CRO has yet to prove structurally.
I can't call this cheap on any honest read - three methods triangulate to roughly $124-$202 and I'm being asked to pay $260. The business is genuinely Solid, but Solid doesn't earn a 70% premium to composite fair value, especially with real leverage and 2025 margin fatigue. This is a 'wait for a better price' setup. I'd want to see it in the $170s before the risk-reward flips, and even then I'd want confirmation the margin dip was one-off. At $260 it's a hold-at-best, and if I owned it I'd trim.
Verify before trusting this (4)
  • 2026 organic revenue growth guide and R&DS backlog conversion rate
  • Segment margin trajectory after 2025's dip - is it cyclical or structural?
  • Net debt path and buyback pace relative to FCF
  • Evidence of real pricing power or AI-data monetization beyond narrative
General Sentiment
+43
Tailwind
tail √Σ 92 · head √Σ 46 · conf 7/10

The prevailing narrative on IQV is a platform-monopoly / AI-enabled data story with strong intensity, and the news flow this week is feeding it directly: an AI Breakthrough Award headline reinforces the AI angle, and a fresh 'Is Wall Street Bullish?' piece frames analysts as highly optimistic. On top of that, the July 28 blowout quarter (top S&P gainer, +14%, raised guide, record bookings) is still the anchoring memory for this name - momentum and analyst tone are aligned to the upside. That is a real, persistent press on the tape, not just background noise.

Tailwinds 3
m62
Active AI-platform narrative with fresh proof point
Strong-intensity platform-monopoly story got a clean, cite-able headline this week (AI Breakthrough Award). That is exactly the kind of news that keeps a narrative-premium name bid, since the story - not fundamentals - is what supports the 100%+ premium to DCF.
m55
Bullish sell-side tone and post-beat afterglow
Media is explicitly framing Wall Street as optimistic, and the July 28 earnings surge (top S&P gainer, raised guide) still anchors sentiment. Target revisions and consensus lean supportive, which sustains inflows into the name.
m40
Peer read-through from CRL rally
Charles River +33% in a month signals rotation and risk appetite back into the CRO/clinical-services cohort. IQV rides that sector sentiment lift even if it is not the lead horse.
Headwinds 2
m35
Narrative running ahead of fundamentals
Story is doing the heavy lifting at a 109% premium to DCF with only moderate durability and low cult coefficient - any crack (bookings miss, pharma R&D budget scare) de-rates fast. This caps upside pressure and creates asymmetric downside if the story wobbles.
m30
Macro rate / valuation ceiling
10y at 4.69% and market PE 25.7 quietly pressure premium-multiple names; with beta 1.18 IQV is more tape-sensitive than a defensive healthcare compounder, so any risk-off flip would sting more than the sector average.
Net pressure is a genuine tailwind, not a euphoric one. The AI/platform narrative is live and getting fed by real news this week, analyst tone is warm, and the July earnings surge is still the reference point in traders' heads. Against that, the tape is only mildly supportive and the stock is carrying a heavy narrative premium that leaves it exposed if the story blinks - so I read it as a Tailwind with confidence around 7, not Strong Tailwind. If the CRO cohort keeps rotating in and no pharma-budget scare hits, this pressure persists for weeks.
Verify before trusting this (5)
  • Whether analyst price-target revisions post Q2 keep climbing or stall
  • Bookings/backlog color at next quarter - the linchpin of the platform story
  • CRO peer tape (CRL, MEDP, ICLR) - if rotation reverses, IQV sentiment follows
  • Any pharma R&D budget cut headlines that would crack the durability of the narrative
  • VIX regime - a move back above 20 would disproportionately hit this beta-1.18 premium name
The market-wide tape + this name's exposure to it (beta / sector / narrative durability). Context on the non-fundamental pressure — not a call on the business or the price. processId: detail-general-sentiment
Growth Outlook
-8
Growing
edge √Σ 94 · risk √Σ 102 · conf 7/10

Two forces dominate. First, pharma is spending more on late-stage development into the 2027-2030 patent cliff while simultaneously running hard cost discipline on commercial and analytics budgets — that mix favours IQVIA's contracted trial work and pressures its higher-margin advisory/analytics line, which is exactly the pattern in the +8.4% revenue / +3.6% operating income split. Second, capital cost matters more than sentiment here: a 4.69% 10-year keeps emerging-biopharma trial starts subdued, and that cohort is where incremental outsourcing growth historically came from. AI is genuinely two-sided for this company: it can compress the billable-hour content of monitoring and data management (revenue risk), but IQVIA's proprietary longitudinal patient and prescription data is the scarce input models need, which is the one asset a competitor cannot rebuild. Net: a durable, slow-compounding business inside a faster-moving category.

Growth drivers 4
m61
Contracted backlog conversion in R&DS
Clinical development revenue is booked years ahead; the latest matched-quarter print (+8.4% revenue) is roughly double the 4.3% multi-year CAGR, which is the signature of backlog burn accelerating rather than a one-off. That gives unusually high visibility on the next 2-4 prints.
m50
TAS data/analytics annuity with contractual escalators
The real-world data and prescription-audit franchise is subscription-like with high renewal and embedded price escalators; it is the reason revenue volatility is only 1.5% and all years have been positive. This is the floor under the growth call, not the upside.
m42
Pharma patent-cliff pipeline spend
The 2027-2030 loss-of-exclusivity wave forces large-cap pharma to push more assets through development and to buy more commercialization analytics; IQVIA is a default vendor at scale, which supports demand even if per-trial pricing is competitive.
m28
EPS leverage from buyback and mix
Net income +10% against operating income +3.6%, plus four straight modest EPS beats (+4%, +3%, +14%), indicates below-the-line and share-count support. It makes the reported EPS line grow faster than the underlying business.
Growth risks 5
m64
Underperformance versus a fast-growing category
Category median recent growth is ~16.3% and industry revenue CAGR 16.1% against IQVIA's 5.9-8.4%; a -12.3pp gap. Even allowing that a $16bn+ incumbent cannot match subsegment growth rates, the direction says peers (Medpace-type, diagnostics-levered names) are taking the incremental dollar.
m54
Margin compression / commoditized service pricing
Operating income growing less than half as fast as revenue while industry margins expand +6.9pp is the clearest signal that clinical services pricing is being competed away and mix is shifting toward lower-value pass-through work.
m40
Biotech funding sensitivity with 10y at 4.69%
Emerging-biopharma bookings — the historic growth engine — are rate-sensitive. A restrictive curve keeps small-cap trial starts and cancellation rates unfavourable, capping the acceleration case.
m36
Large-pharma insourcing and R&D budget discipline
Post-IRA cost programs at major clients cut discretionary analytics spend first and pull selective trial work in-house; backlog cancellations are the transmission mechanism and they show up with a 2-3 quarter lag.
m22
Leverage limits reinvestment optionality
A levered balance sheet means growth must be funded from cash flow (FCF CAGR 16.9% helps), but it constrains the ability to buy the fast-growing data/AI assets that would close the category gap.
vs expectations: ~6m inline · 1y inline · 2-3y below
The forward growth verdict — is the business itself likely to grow (next 2 quarters / year 1 / years 2–3), judged against its category and against printed expectations. The full horizon ladder + creme renders on the Growth Outlook card above. Not a call on the price (Valuation owns that) or the tape (Sentiment owns that).
Please log in to view trade setups
The Augustus trade-setup read is a members feature.
Log in
Lenses kept deliberately separate — Company Quality (price-agnostic), Valuation (price-conditional), General Sentiment (non-fundamental macro/narrative pressure), and Growth Outlook (the forward growth verdict). The scores are not blended. Filing-level items (convertibles, lock-ups, customer concentration) are v2 — see each lens's "verify."
Price Prediction
Lower -10.7% v0.6.0 View full prediction →

When we made this prediction on Aug 23, 2026, IQV was $259.82. We expect it to be $232.00 by Feb 2027, and we consider it great value under $175.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 23, 2026.

Price when predicted$259.82
Our estimate for Feb 2027$232.00-10.7%
Great value below$175.00
Price history shown (6 Months)

Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.

Community AI Feedback
No community reviews yet for IQV. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
v1.1.562 · 9b2927c4 · 2026-08-22 16:52:06